News
![Clovis Oncology to Present at the Bank of America Health Care Conference 2020](/assets/news/news1-f26f2455ece0c3cbea64441818e795358cadddddb27e796f883ae2bd06f66139.png)
Clovis Oncology to Present at the Bank of America Health Care Conference 2020
Clovis Oncology, Inc. (Nasdaq: CLVS) today announced that its President and Chief Executive Officer, Patrick J. Mahaffy, will present at the Bank of America Health Care Conference 2020 on Tuesday
![Formycon: Neues Corona-Medikament im Visier!](/assets/news/news15-207f60e93f55a63563671c62b1e07d0bc426e50a03c286a608f29c8138f4f1de.png)
Formycon: Neues Corona-Medikament im Visier!
Formycon (WKN: A1EWVY) stellt sich der Herausforderung der Dekade: Die Münchner Biosimilar-Schmiede nimmt den Kampf gegen COVID-19 auf. Die langjährige Expertise seiner Mediziner ermögliche eine
![Lysogene Reports Its Cash Position as of 31 March 2020](/assets/news/news19-14feaf1b3ac689101974b5354f2ab8bb5cb2e7cb49a06b120b8491e9ebba31f4.png)
Lysogene Reports Its Cash Position as of 31 March 2020
Regulatory News:
Lysogene (Paris:LYS) (FR0013233475 – LYS), a Phase 3 gene therapy platform company targeting central nervous system (CNS) diseases, today reports its cash position as of 31 March
![Sensorion Announces It Will Hold Its General Assembly on May 20, 2020 Behind Closed Doors Alongside the Publication of Its 2019 Annual Financial Report](/assets/news/news3-3816cd3656012f9a06bae00ff06108b383643da017a8247fff474f84ea8a7c5a.png)
Sensorion Announces It Will Hold Its General Assembly on May 20, 2020 Behind Closed Doors Alongside the Publication of Its 2019 Annual Financial Report
Regulatory News:
Sensorion (Paris:ALSEN) (FR0012596468 – ALSEN) a pioneering clinical-stage biotech company that specializes in the development of novel therapies to restore, treat and prevent
![Sangamo Therapeutics Announces Presentations at 2020 Annual Meeting of the American Society of Gene & Cell Therapy](/assets/news/news17-d49b9ce9c87babddea210274f0f8d00a1cf706146ef6382020cc7ece83b76f6c.png)
Sangamo Therapeutics Announces Presentations at 2020 Annual Meeting of the American Society of Gene & Cell Therapy
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced the acceptance of several abstracts for presentation at the 23rd Annual Meeting of the American Society of
![PFIZER REPORTS FIRST-QUARTER 2020 RESULTS](/assets/news/news17-d49b9ce9c87babddea210274f0f8d00a1cf706146ef6382020cc7ece83b76f6c.png)
PFIZER REPORTS FIRST-QUARTER 2020 RESULTS
Pfizer Inc. (NYSE: PFE) reported financial results for first-quarter 2020, reaffirmed its 2020 financial guidance for revenues and Adjusted diluted EPS(3) and updated certain other components of
![Novocure Announces Presentation of EF-19 Post-approval Registry Trial Data Studying Optune as a Monotherapy for the Treatment of Recurrent GBM at the American Association for Cancer Research 2020 Virtual Annual Meeting I](/assets/news/news18-f135f6c168ef56d2b112890081403b0a310104acfadbf4a8f72634bd390e98ac.png)
Novocure Announces Presentation of EF-19 Post-approval Registry Trial Data Studying Optune as a Monotherapy for the Treatment of Recurrent GBM at the American Association for Cancer Research 2020 Virtual Annual Meeting I
Novocure (NASDAQ: NVCR) today announced that an abstract highlighting results from the EF-19 post-approval registry trial studying Optune for the treatment of recurrent GBM will be presented as a
![Aurinia Appoints Joe Miller as Chief Financial Officer](/assets/news/news16-82a218458f0e15ae617f9186b258dfd3add112716106c6ee3cbb48563ccdef52.png)
Aurinia Appoints Joe Miller as Chief Financial Officer
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSX:AUP) (“Aurinia” or the “Company”), a late-stage clinical biopharmaceutical company focused on advancing voclosporin in multiple indications, today
![BB Biotech: So geht Rendite mit COVID-19-Aktien!](/assets/news/news11-1ebbf8540812dc8f080ecfeb67ce19c492651a7c439bd800cec2630c3a04a840.png)
BB Biotech: So geht Rendite mit COVID-19-Aktien!
Interessante Einblicke in den Geschäftsverlauf im Auftaktquartal liefert heute BB Biotech (WKN: A0NFN3). Die mussten zwar Rückschläge einstecken, glänzten aber auch durch Überraschungen – die mit
![Epigenomics: US-News lockt Käufer in Aktie!](/assets/news/news1-f26f2455ece0c3cbea64441818e795358cadddddb27e796f883ae2bd06f66139.png)
Epigenomics: US-News lockt Käufer in Aktie!
Positive Nachrichten aus den USA schicken die Epigenomics-Aktie (WKN: A11QW5) heute in dunkelgrünes Terrain. Der Kurs gewinnt im Xetra-Handel um +8,21% auf 1,12 Euro.
Die deutsch-amerikanische
![Sensorion reschedules General Assembly to May 20](/assets/news/news15-207f60e93f55a63563671c62b1e07d0bc426e50a03c286a608f29c8138f4f1de.png)
Sensorion reschedules General Assembly to May 20
Regulatory News:
Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotech company which specializes in the development of novel therapies to restore, treat and prevent within the
![GSK Presents New Data from the GARNET Study Demonstrating Potential of Dostarlimab to Treat a Subset of Women with Recurrent or Advanced Endometrial Cancer](/assets/news/news18-f135f6c168ef56d2b112890081403b0a310104acfadbf4a8f72634bd390e98ac.png)
GSK Presents New Data from the GARNET Study Demonstrating Potential of Dostarlimab to Treat a Subset of Women with Recurrent or Advanced Endometrial Cancer
GlaxoSmithKline plc (LSE/NYSE:GSK) today announced data from an updated analysis of the GARNET trial, which demonstrated that dostarlimab, an investigational anti-programmed death-1 (PD-1)
![Puma Biotechnology to Host Conference Call to Discuss First Quarter Financial Results](/assets/news/news16-82a218458f0e15ae617f9186b258dfd3add112716106c6ee3cbb48563ccdef52.png)
Puma Biotechnology to Host Conference Call to Discuss First Quarter Financial Results
Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, will host a conference call at 1:30 p.m. PDT/4:30 p.m. EDT on Thursday, May 7, 2020, following the release of its first quarter
![Pfizer Hosts Virtual-Only Annual Meeting of Shareholders](/assets/news/news6-ad07925a95156ae03dbe17caf44a9dc29f254ff2c2a42c7678d35288ad55cec8.png)
Pfizer Hosts Virtual-Only Annual Meeting of Shareholders
The board of directors of Pfizer Inc. (NYSE:PFE) today declared a 38-cent second-quarter 2020 dividend on the company’s common stock, payable June 5, 2020 to shareholders of record at the close of
![QIAGEN N.V. to Report First Quarter 2020 Results](/assets/news/news7-ff65ae96e2a4b99929975e34f30f51b3393455f312fc86852d9fc8020c5054eb.png)
QIAGEN N.V. to Report First Quarter 2020 Results
QIAGEN N.V. (NYSE: QGEN) (Frankfurt Stock Exchange: QIA) announced today that it plans to release its report on results for the first quarter 2020 results on Wednesday, May 6, at approximately 22:0
![Gilead Sciences: Einfach kein entscheidender Durchbruch!](/assets/news/news17-d49b9ce9c87babddea210274f0f8d00a1cf706146ef6382020cc7ece83b76f6c.png)
Gilead Sciences: Einfach kein entscheidender Durchbruch!
Die Aktie von Gilead Sciences (WKN: 885823) steht zuletzt, aufgrund der Covid-19-Pandemie, immer wieder im Mittelpunkt des Anlegerinteresses (wir berichteten). So beflügelte die Aktie kürzlich sogar
![Navidea Biopharmaceuticals Provides Statement Regarding COVID-19 Pandemic](/assets/news/news6-ad07925a95156ae03dbe17caf44a9dc29f254ff2c2a42c7678d35288ad55cec8.png)
Navidea Biopharmaceuticals Provides Statement Regarding COVID-19 Pandemic
Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, announces the
![Lysogene Reports Full Year 2019 Financial Results and Provides Operational Update](/assets/news/news11-1ebbf8540812dc8f080ecfeb67ce19c492651a7c439bd800cec2630c3a04a840.png)
Lysogene Reports Full Year 2019 Financial Results and Provides Operational Update
Regulatory News:
Lysogene (Paris:LYS) (FR0013233475 – LYS), a pioneering Phase 3 gene therapy platform company targeting central nervous system (CNS) diseases, today announced its 2019 financial
![IMV to Participate in Adelaide Capital’s Virtual COVID & Healthcare Mini Conference](/assets/news/news7-ff65ae96e2a4b99929975e34f30f51b3393455f312fc86852d9fc8020c5054eb.png)
IMV to Participate in Adelaide Capital’s Virtual COVID & Healthcare Mini Conference
IMV Inc. (Nasdaq: IMV; TSX: IMV) a clinical-stage biopharmaceutical company, today announced that Company’s management will be participating in Adelaide Capital’s Virtual COVID & Healthcare Mini
![Clovis Oncology to Announce First Quarter 2020 Financial Results and Host Webcast Conference Call on May 5](/assets/news/news16-82a218458f0e15ae617f9186b258dfd3add112716106c6ee3cbb48563ccdef52.png)
Clovis Oncology to Announce First Quarter 2020 Financial Results and Host Webcast Conference Call on May 5
Clovis Oncology, Inc. (NASDAQ: CLVS) will announce its first quarter 2020 financial results on Tuesday, May 5, 2020, after the close of the U.S. financial markets. Clovis’ senior management will
![VALBIOTIS veröffentlicht Jahresergebnisse für 2019](/assets/news/news5-af8c677c86bb4b693f58afef33877e6f798ff0d7e2b4fa69b6e89960549b5ee6.png)
VALBIOTIS veröffentlicht Jahresergebnisse für 2019
VALBIOTIS (Paris:ALVAL) (FR0013254851 – ALVAL / PEA/KMU-qualifiziert), ein Forschungs- und Entwicklungsunternehmen mit Schwerpunkt auf wissenschaftlicher Innovation zur Vorbeugung und Bekämpfung
![Mogrify and Sangamo announce collaboration and exclusive license agreement for Mogrify’s iPSC- and ESC-derived regulatory T cells](/assets/news/news17-d49b9ce9c87babddea210274f0f8d00a1cf706146ef6382020cc7ece83b76f6c.png)
Mogrify and Sangamo announce collaboration and exclusive license agreement for Mogrify’s iPSC- and ESC-derived regulatory T cells
Mogrify Ltd (Mogrify®), a UK company aiming to transform the development of cell therapies by the systematic discovery of novel cell conversions, and Sangamo Therapeutics (Sangamo) (Nasdaq: SGMO)
![4SC: Bald wissen alle mehr!](/assets/news/news18-f135f6c168ef56d2b112890081403b0a310104acfadbf4a8f72634bd390e98ac.png)
4SC: Bald wissen alle mehr!
Im Rahmen ihrer heute vorgelegten Zwischenmitteilung zum ersten Quartal informiert die Münchner Biotechschmiede 4SC (WKN: A14KL7) über wesentliche Ereignisse und gibt einen Überblick über die